influenza
virus
exhibit
fascin
level
antigen
heterogen
facilit
reinfect
human
popul
human
antibodi
repertoir
also
manifest
endless
capabl
variat
gene
specifi
portion
antibodi
molecul
interact
epitop
recent
explos
techniqu
isol
human
monoclon
antibodi
virus
led
isol
new
antibodi
allow
glimps
molecular
basi
recognit
escap
underli
constant
antigen
drift
influenza
surfac
protein
studi
also
reveal
evid
lifelong
persist
immun
influenza
virus
vaccin
acut
virus
princip
work
induc
neutral
antibodi
understand
molecular
basi
viru
neutral
antibodi
import
remark
littl
progress
past
understand
action
individu
human
antibodi
difficulti
gener
human
monoclon
antibodi
function
activ
virus
recent
technic
breakthrough
howev
facilit
isol
new
human
monoclon
antibodi
virus
influenza
care
studi
molecular
basi
specif
crossreact
examin
molecular
mechan
viru
inhibit
shed
new
light
import
interfac
viral
antigen
human
immun
system
learn
intric
surfac
interact
protein
molecul
gain
insight
might
ration
design
redesign
viral
antigen
vaccin
induc
enhanc
antibodi
respons
broader
reactiv
goal
understand
induc
broadli
crossreact
neutral
antibodi
particularli
relev
influenza
studi
yearli
antigen
drift
field
strain
also
interest
design
vaccin
prevent
chronic
viral
infect
like
hiv
hepat
c
monoclon
antibodi
mab
revolution
conduct
scienc
sinc
first
descript
use
specif
reagent
also
made
possibl
improv
clinic
diagnost
medic
arena
larg
number
antibodi
found
way
clinic
use
therapeut
agent
typic
therapi
cancer
autoimmun
one
antibodi
palivizumab
licens
prevent
viral
diseas
rsv
infect
nevertheless
potenti
mab
therapi
remain
larg
unfulfil
princip
reason
lack
larg
number
mab
therapeut
simpli
difficulti
gener
human
mab
high
affin
virusspecif
antibodi
prevent
mani
import
viru
infect
diseas
specif
human
antibodi
shown
prevent
diseas
caus
wide
varieti
virus
belong
divers
rna
dna
viru
famili
includ
orthomyxovirus
paramyxovirus
alphavirus
flavivirus
arenavirus
lentivirus
picornavirus
hepadnavirus
poxvirus
herpesvirus
exampl
clinic
medicin
includ
hepat
viru
hav
measl
viru
polioviru
varicella
zoster
viru
number
polyclon
immunoglobulin
ig
product
licens
use
us
strike
polyclon
ig
prepar
high
titer
specif
agent
use
number
virus
includ
varicella
zoster
viru
ig
hepat
b
viru
ig
rsv
ig
rabi
viru
ig
vaccinia
viru
ig
cytomegaloviru
ig
difficulti
abil
sustain
product
includ
need
find
immun
donor
risk
adventiti
agent
humanderiv
blood
product
signific
lottolot
variabl
donor
pool
human
mab
desir
replac
therapi
mean
therapi
condit
whether
infecti
diseas
noninfecti
health
problem
autoimmun
cancer
varieti
techniqu
gener
human
mab
use
gener
candid
mab
therapeut
first
mab
murin
mab
develop
fusion
murin
splenocyt
nonsecret
myeloma
mice
offer
mani
advantag
gener
mab
notabl
opportun
hyperimmun
subject
abil
collect
lymphoid
tissu
includ
spleen
murin
mab
use
past
patient
moder
success
exampl
earli
trial
began
treat
patient
experienc
transplant
reject
antithymocyt
murin
mab
although
abrog
reject
could
achiev
case
patient
treat
intens
care
unit
signific
proport
patient
suffer
system
side
effect
includ
lifethreaten
anaphylaxi
sever
reaction
due
human
antimous
antibodi
hama
reaction
besid
anaphylaxi
hama
also
caus
subtl
effect
acceler
clearanc
therapeut
antibodi
infus
approxim
us
popul
antimous
antibodi
follow
infus
mous
antibodi
virtual
subject
exhibit
hama
respons
therefor
effort
made
reduc
immunogen
murin
mab
replac
murin
sequenc
outsid
antigencombin
site
human
antibodi
sequenc
antibodi
gene
clone
techniqu
made
possibl
recombin
mean
initi
human
antibodi
fc
region
clone
onto
mous
fab
region
yield
socal
chimer
antibodi
antibodi
could
still
induc
hama
howev
suggest
signific
proport
hama
respons
direct
constant
region
c
h
c
l
domain
antibodi
subsequ
heroic
effort
center
antibodi
human
process
also
known
cdrgraft
method
variabl
loop
mous
mab
antibodi
combin
site
complementar
determin
region
cdr
loop
clone
onto
human
fab
framework
predict
threedimension
model
similar
overal
conform
mous
fab
six
cdr
cdr
heavi
chain
cdr
light
chain
must
clone
correctli
often
affin
function
activ
human
antibodi
significantli
reduc
lost
compar
parent
murin
mab
model
suggest
particular
framework
residu
revert
back
mous
sequenc
order
restor
origin
conform
sometim
variabl
domain
amino
acid
also
found
immunogen
human
variabl
domain
resurfac
requir
surfac
residu
normal
found
human
variabl
fragment
fv
mutat
expect
human
amino
acid
therebi
elimin
potenti
immunogen
site
engin
process
labori
time
consum
without
guarante
success
combinatori
antibodi
phage
display
librari
yield
human
antibodi
princip
drawback
approach
mani
antibodi
fragment
fab
singl
chain
fv
bind
antigen
mediat
function
desir
antibodi
viru
neutral
therefor
rapid
screen
procedur
phagefab
express
antibodi
fragment
often
miss
antibodi
interest
convert
candid
fab
fulllength
ig
molecul
labori
process
challeng
highthroughput
screen
purpos
although
compani
begun
use
highthroughput
techniqu
base
small
molecul
librari
screen
model
investig
attempt
combin
advantag
mous
model
use
human
b
cell
antibodi
gene
research
transplant
human
peripher
blood
lymphocyt
pbl
vaccin
healthi
blood
donor
mice
sever
combin
immunodefici
human
pblscid
mice
demonstr
antigendepend
humor
immun
respons
engraft
rate
low
howev
scid
mice
provid
environ
somat
mutat
ig
variabl
gene
take
place
effici
approach
also
combin
phage
display
antibodi
repertoir
clone
yield
human
fab
similar
approach
trimera
system
humanmous
radiat
chimera
model
function
human
lymphocyt
engraft
normal
strain
mice
render
immunoincompet
lethal
total
bodi
irradi
follow
radioprotect
sever
combin
immunodefici
scid
mous
bone
marrow
high
affin
secondari
antibodi
respons
gener
difficult
achiev
method
transgen
mice
contain
inactiv
mous
ig
gene
larg
region
human
heavi
light
chain
loci
clone
yeast
artifici
chromosom
yac
develop
mice
possess
human
heavi
chain
yac
germlin
configur
core
variabl
constant
sequenc
j
h
c
v
h
gene
human
kappa
chain
yac
contain
germlin
configur
j
c
region
v
l
gene
support
product
highaffin
human
antibodi
antigen
mice
use
commerci
set
develop
new
antibodi
anoth
approach
develop
therapeut
mab
use
human
gener
nonhuman
primat
mab
chimpanze
human
highli
relat
genet
therefor
develop
human
antichimpanze
immunoglobulin
antibodi
human
patient
expect
rare
sequenc
analysi
indic
human
antibodi
gene
highli
homolog
correspond
chimpanze
gene
differ
compar
differ
human
allotyp
studi
other
human
antibodi
halflif
chimpanze
antibodi
follow
infus
chimpanze
util
approach
sever
limit
howev
scarciti
primat
studi
human
mab
deriv
peripher
blood
lymphocyt
pbl
research
volunt
patient
desir
howev
mani
technic
difficulti
result
limit
yield
effort
develop
human
mab
past
sever
method
gener
human
mab
describ
method
primarili
reli
transform
b
cell
epsteinbarr
viru
ebv
fusion
transform
b
cell
nonsecret
myeloma
cell
murin
human
murinehuman
heteromyeloma
origin
ebv
transform
histor
yield
antibodi
low
effici
low
affin
predominantli
igm
class
cell
line
often
unstabl
cultur
limit
especi
import
seek
use
limit
amount
donor
lymphocyt
number
antigenspecif
bcell
usual
low
even
follow
activ
immun
infect
recent
innov
combin
use
ebv
transform
simultan
cpg
treatment
stimul
tolllik
receptor
result
mark
enhanc
effici
transform
process
techniqu
led
isol
interest
antibodi
sar
coronaviru
avian
influenza
among
other
techniqu
also
combin
electrofus
isol
rare
antibodi
influenza
convent
fusion
techniqu
princip
polyethylen
glycol
peg
mediat
fusion
hamper
low
frequenc
fusion
immort
fuse
murin
splenocyt
hyperimmun
anim
extrem
low
ineffici
toler
one
simpli
aim
find
one
sever
mab
bind
antigen
howev
use
human
sampl
pbl
ultim
even
preciou
sampl
tumor
infiltr
lymphocyt
ineffici
make
success
unlik
develop
high
effici
electrofus
method
make
gener
human
mab
limit
number
donor
cell
possibl
applic
high
intens
electr
field
puls
cell
caus
transient
membran
permeabil
extent
permeabil
depend
sever
physic
paramet
associ
techniqu
puls
intens
number
durat
shape
interv
electr
field
intens
critic
paramet
induct
permeabil
intens
must
exceed
critic
threshold
order
induc
membran
permeabil
electr
field
intens
deliv
depend
cell
size
extent
permeabil
correl
experiment
flow
rate
across
membran
control
puls
number
durat
increas
electr
field
intens
critic
threshold
need
permeabil
result
increas
area
membran
involv
permeabil
transient
disappear
time
deliveri
electr
field
puls
rate
reseal
pore
membran
may
influenc
puls
durat
number
independ
electr
field
intens
creat
permeabil
membran
effect
appli
electr
field
electrofus
similar
electropor
except
membran
close
contact
fuse
togeth
process
pore
format
therefor
electr
field
intens
use
electrofus
similar
use
electropor
electrofus
perform
sequenc
step
first
cell
brought
contact
cell
cellcel
contact
achiev
sever
method
chemic
method
avidinbiotin
bridg
use
specif
bring
togeth
two
cell
type
chemic
method
requir
manipul
method
use
certain
circumst
physic
method
centrifug
bring
cell
contact
prior
fusion
puls
electroacoust
fusion
cell
sugar
solut
cell
brought
contact
ultrason
stand
wave
field
describ
use
method
bring
cell
contact
prior
electrofus
term
dielectrophoresi
fusion
method
suffici
forc
must
appli
cell
overcom
neg
surfac
charg
electr
use
mere
appli
uniform
electr
field
move
cell
net
charg
cell
zero
howev
nonuniform
field
move
posit
ion
insid
cell
one
side
neg
ion
opposit
side
produc
dipol
dipol
induc
net
forc
exert
cell
intens
field
greater
one
side
movement
cell
one
direct
caus
cell
concentr
area
sinc
cell
dipol
neg
side
one
cell
attract
posit
side
anoth
cell
come
neg
surfac
charg
figur
illustr
principl
figur
lowvoltag
altern
current
ac
deliv
mix
cell
suspens
transform
b
cell
myeloma
cell
b
cell
mixtur
field
result
myelomab
cell
contact
c
result
field
caus
format
pearl
chain
mix
cell
establish
close
contact
use
ac
current
larg
electropor
direct
current
dc
puls
deliv
figur
follow
mainten
contact
deliveri
ac
puls
time
membran
reseal
myeloma
cell
fuse
antigenspecif
b
cell
recent
develop
techniqu
sort
circul
human
plasmablast
develop
excel
effici
isol
human
influenzaspecif
antibodi
investig
note
plasmablast
normal
found
peripher
blood
substanti
number
occur
high
frequenc
blood
subject
vaccin
influenza
vaccin
week
prior
time
circul
cell
suggest
like
possess
gene
specif
vaccin
antigen
molecular
clone
express
antibodi
gene
subsequ
prove
influenzaspecif
antibodi
gene
common
cell
techniqu
promis
yield
larg
number
antibodi
influenza
convent
experiment
vaccin
use
immunogen
human
clear
time
whether
circul
pool
plasmablast
patient
chronic
infect
hiv
hepat
c
enrich
antigenspecif
clone
also
establish
cell
transform
effici
therefor
direct
clone
antibodi
gene
follow
express
antibodi
requir
screen
recent
explos
human
antibodi
techniqu
yield
interest
mab
influenza
viru
recent
year
phage
display
techniqu
yield
interest
crossreact
antibodi
recogn
larg
number
divers
influenza
strain
antibodi
great
interest
although
seem
doubt
knowledg
epitop
immedi
use
induc
crossreact
antibodi
epitop
present
circul
influenza
strain
individu
possess
signific
level
antibodi
despit
previou
infect
studi
focus
occurr
highli
potent
human
neutral
antibodi
pandem
influenza
strain
isol
elderli
survivor
pandem
sever
interest
featur
studi
highlight
remark
extrem
elderli
subject
maintain
circul
b
cell
encod
antibodi
influenza
viru
year
pandem
viru
antigen
similar
virus
circul
human
first
sever
decad
th
centuri
therefor
expect
pandem
survivor
would
expos
probabl
infect
similar
virus
multipl
occas
childhood
earli
adult
year
howev
half
centuri
sinc
antigen
relat
virus
circul
human
surprisingli
nearli
extrem
elderli
subject
examin
younger
subject
possess
b
cell
peripher
blood
frequenc
low
averag
million
circul
cell
haspecif
extent
studi
rais
question
answer
signal
maintain
b
cell
circul
earli
th
centuri
influenza
antigen
persist
subject
subject
genet
unusu
way
isol
antibodi
sequenc
provid
glimps
natur
immun
memori
mechan
maintain
antibodi
isol
ha
pandem
survivor
exhibit
distinct
molecular
featur
interestingli
antibodi
gene
sequenc
possess
high
number
somat
mutat
nearli
three
time
averag
number
mutat
found
sequenc
human
memori
b
cell
intuit
one
might
specul
high
number
somat
mutat
would
facilit
high
affin
bind
found
true
biosensor
studi
reveal
antibodi
interact
extraordinari
affin
recombin
ha
molecul
final
test
whether
high
affin
interact
correl
high
function
activ
inde
antibodi
exhibit
ultrapot
neutral
activ
viru
earli
th
centuri
virus
measur
hai
neutral
antibodi
assay
vitro
protect
lethal
challeng
mice
typic
influenza
neutral
antibodi
recogn
variabl
loop
ha
protein
head
surround
sialic
acid
receptor
bind
site
five
major
antigen
site
previous
defin
use
murin
monoclon
antibodi
design
site
sa
sb
cb
figur
use
gener
antibodi
escap
mutant
coupl
ha
gene
sequenc
analysi
techniqu
identifi
viru
specif
human
antibodi
bind
princip
sa
sb
antigen
site
data
suggest
potent
inhibit
antibodi
bind
convent
site
locat
highli
access
also
variabl
loop
interestingli
bind
appear
involv
residu
flank
classic
site
suggest
human
antibodi
may
interfac
ha
somewhat
broader
interfac
articul
surfac
murin
antibodi
ongo
structur
studi
reveal
exact
natur
interact
extent
shape
complementar
human
antibodi
abl
achiev
one
surpris
featur
epitop
studi
fact
one
antibodi
design
exhibit
low
level
crossreact
number
virus
th
centuri
antibodi
unexpectedli
bind
inhibit
viru
far
apart
virus
although
activ
highest
strain
better
understand
structur
basi
crossreact
could
suggest
conserv
element
ha
molecul
could
focu
vaccin
develop
vaccin
induc
broadli
crossreact
antibodi
isol
addit
crossreact
antibodi
head
domain
influenza
high
prioriti
understand
structur
basi
conserv
otherwis
cryptic
conserv
epitop
detail
understand
molecular
basi
antibodymedi
inhibit
influenza
human
antibodi
possibl
past
pauciti
human
monoclon
antibodi
recent
technic
develop
field
human
monoclon
antibodi
isol
divers
techniqu
includ
phage
display
singl
b
cell
sort
clone
plasmablast
sort
clone
ebvcpg
transform
b
cell
human
hybridoma
techniqu
begun
yield
larg
number
interest
influenza
specif
antibodi
studi
genet
structur
basi
neutral
crossreact
lead
way
ration
input
design
select
ha
molecul
inclus
vaccin
especi
design
vaccin
induc
broadli
neutral
antibodi
major
antigen
site
influenza
hemagglutinin
molecul
ribbon
diagram
base
pdb
entri
design
antigen
site
describ
previous
asterisk
indic
site
human
neutral
antibodi
isol
